Globenewswire·2025-09-30 15:16Core Points - Class action lawsuits have been filed on behalf of shareholders of Novo Nordisk A/S and Lineage, Inc. due to alleged misleading statements and failure to disclose material adverse facts about their business operations and prospects [2][3]. Novo Nordisk A/S - The class period for Novo Nordisk is from May 7, 2025, to July 28, 2025, with a lead plaintiff deadline of September 30, 2025 [2]. - The complaint alleges that the company ignored the significance of the personalization exception for GLP-1 compounding and overestimated its ability to capture patients transitioning from compounded treatments [2]. - Defendants' positive statements regarding the company's business were deemed materially misleading and lacked a reasonable basis [2]. Lineage, Inc. - The class period for Lineage is from July 22, 2025, to August 1, 2025, also with a lead plaintiff deadline of September 30, 2025 [3]. - The complaint states that Lineage experienced a decline in customer demand due to increased cold-storage supply and a shift in customer inventory strategies post-COVID-19 [3]. - It is alleged that the company implemented unsustainable price increases prior to its IPO and was unable to counteract adverse trends, leading to stagnant or falling revenue and occupancy rates [3]. - Similar to Novo Nordisk, the positive statements made by Lineage regarding its business operations were also considered materially misleading [3].